Top Markets
#1 Black Phoenix Black Phoenix +736.72%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +18.03%
#3 Verus Coin Verus Coin +14.55%
#4 Gas Gas +9.22%
#5 MetaDAO MetaDAO +7.78%
#6 Ontology Ontology +5.23%
#7 wojak wojak +5.13%
#8 StonkBroker StonkBroker +4.52%
#9 Polymesh Polymesh +3.86%
#10 Wibx Wibx +3.79%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Beijing Tiantan Biological Products Co., Ltd. Beijing Tiantan Biological Products Co., Ltd.

Beijing Tiantan Biological Products Co., Ltd.

600161
Rank in Stocks #4521
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
Share Price
$1.81
Market Cap
$3.59B
Change (1 day)
1.62%
Change (1 year)
-37.06%
Country
CN
Trade Beijing Tiantan Biological Products Co., Ltd. (600161)

Category

Healthcare
Revenue for Beijing Tiantan Biological Products Co., Ltd. (600161)
Revenue in Aug 2026 TTM: 0
According to Beijing Tiantan Biological Products Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Beijing Tiantan Biological Products Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH